These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 10640928)

  • 1. Myeloma-associated systemic amyloidosis presenting as chronic paronychia and palmodigital erythematous swelling and induration of the hands.
    Ahmed I; Cronk JS; Crutchfield CE; Dahl MV
    J Am Acad Dermatol; 2000 Feb; 42(2 Pt 2):339-42. PubMed ID: 10640928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe amyloidosis with mild multiple myeloma--an unusual course.
    Zeidman A; Sender BZ; Yarmolovsky A; Fradin Z; Mittelman M
    Haematologia (Budap); 2000; 30(1):55-9. PubMed ID: 10841327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary systemic amyloidosis with delayed progression to multiple myeloma.
    Rajkumar SV; Gertz MA; Kyle RA
    Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapy options in systemic AL-amyloidosis with renal involvement].
    Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
    Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
    Fuchida S; Okano A; Hatsuse M; Murakami S; Haruyama H; Shimazaki C
    Rinsho Ketsueki; 2012 Nov; 53(11):1937-9. PubMed ID: 23257677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma with amyloidosis presenting with recurrent gastrointestinal bleeding.
    Alvares JF; Thomas J; Ramakrishna K; Rao L; Rao AC
    Indian J Gastroenterol; 2003; 22(5):196. PubMed ID: 14658543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
    Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
    Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloma-associated systemic amyloidosis presenting as digital nodules.
    Miyagawa S; Fukumoto T; Tsukaguchi N; Hoshii Y; Ishihara T
    Br J Dermatol; 2002 Sep; 147(3):602. PubMed ID: 12207610
    [No Abstract]   [Full Text] [Related]  

  • 9. [Amyloidosis associated with multiple myeloma].
    Hirota K; Furusawa S
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):480-3. PubMed ID: 9851195
    [No Abstract]   [Full Text] [Related]  

  • 10. Bullous amyloidosis.
    Beacham BE; Greer KE; Andrews BS; Cooper PH
    J Am Acad Dermatol; 1980 Nov; 3(5):506-10. PubMed ID: 7012198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fingertip dermatitis refractory to topical corticosteroids associated with nail-patella syndrome.
    Sakata S; Opie J; Howard A
    Australas J Dermatol; 2008 Feb; 49(1):55-6. PubMed ID: 18186852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pleural effusion as a first sign of Ig D lambda multiple myeloma].
    Maachi M; Fellahi S; Diop ME; Francois T; Capeau J; Bastard JP
    Ann Med Interne (Paris); 2003 Feb; 154(1):70-2. PubMed ID: 12746663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Follicular mucinosis with generalized para-amyloidosis as a cutaneous paraneoplastic syndrome in myeloma (IgD and light chain plasmacytoma). A demonstration of the course using melphalan-prednisone therapy with a 3 years remission].
    Jänner M; Lippert HD; Stolzenbach G
    Z Hautkr; 1977 Aug; 52(16):873-40. PubMed ID: 408988
    [No Abstract]   [Full Text] [Related]  

  • 14. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of amyloidosis in multiple myeloma.
    Mehta AD
    Br J Clin Pract; 1978 Dec; 32(12):358-9, 61. PubMed ID: 737115
    [No Abstract]   [Full Text] [Related]  

  • 16. Paronychia.
    Bonifaz A; Paredes V; Fierro L; López-Lozano H; de la Herrán P; Vázquez-González D
    Skinmed; 2013; 11(1):14-6. PubMed ID: 23540071
    [No Abstract]   [Full Text] [Related]  

  • 17. Unusual milia amyloidosis as initial signs of multiple myeloma-associated systemic amyloidosis.
    Ohashi T; Kikuchi N; Yamamoto T
    Int J Dermatol; 2013 Aug; 52(8):981-2. PubMed ID: 23869927
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Falk RH; Berk JL; Dember LM; Finn KT; Skinner M
    Br J Haematol; 2002 Jun; 117(4):886-9. PubMed ID: 12060126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis.
    Reyes CM; Rudinskaya A; Kloss R; Girardi M; Lazova R
    J Clin Rheumatol; 2008 Jun; 14(3):161-5. PubMed ID: 18525436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
    Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.